<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some <z:chebi fb="4" ids="48705">agonists</z:chebi> of the peroxisome proliferator-activated receptor gamma (PPARgamma) belonging to the thiazolidinedione (TZD) family, as well as the cyclopentenone <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> 15-dPGJ2, have been shown to cause neuroprotection in animal models of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We have tested whether the TZD-unrelated PPARgamma <z:chebi fb="4" ids="48705">agonist</z:chebi> L-796,449 is neuroprotective after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in the rat brain </plain></SENT>
<SENT sid="2" pm="."><plain>Our results show that L-796,449 decreases MCAO-induced <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improves neurologic scores </plain></SENT>
<SENT sid="3" pm="."><plain>This protection is concomitant to inhibition of MCAO-induced brain expression of inducible NO synthase (iNOS) and the matrix metalloproteinase MMP-9 and to upregulation of the cytoprotective stress protein <z:chebi fb="4" ids="30413">heme</z:chebi> oxygenase-1 (HO-1) </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of the NF-kappaB p65 monomer and the NF-kappaB inhibitor IkappaBalpha protein levels as well as gel mobility shift assays indicate that L-796,449 inhibits NF-kappaB signaling, and that it may be recruiting both PPARgamma-dependent and independent pathways </plain></SENT>
<SENT sid="5" pm="."><plain>In summary, our results provide new insights for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
</text></document>